Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Nov 5;12:400. doi: 10.3389/fncel.2018.00400

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2018 Gu, Hu, Wu, Mu, Ren, Liu and Wang.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

P7C3 inhibited LPS-induced transcriptional activation of pro-inflammatory factors in BV2 cells. (A) BV2 cells were pretreated with P7C3 (0.1, 1, or 10 μM) for 2 h and then exposed to LPS (100 ng/mL) for 6 h. After treatment, cell lysate was collected to measure the mRNA levels of iNOS, COX-2, IL-6 and TNFα using qRT-PCR assays. The values are presented as the means ± SEM from three independent experiments. Kruskal–Wallis test followed by the Iman-Conover method for multiple comparison between groups was performed, *P < 0.05, **P < 0.01 vs. the group treated with LPS. (B) BV2 cells were pretreated with P7C3 (10 μM) for 2 h and then exposed to LPS (100 ng/mL) for 6 h. After culture, cell lysate was collected and the mRNA levels of Arg1, IL-10, CD206 were measured using qRT-PCR assays. (C) BV2 cells were administrated with P7C3 (10 μM) for 2 h followed by IL-4 (20 ng/mL) treatment or IL-4 (20 ng/mL) plus LPS (100 ng/mL) treatment for 6 h. The mRNA levels of Arg1, IL-10, CD206 in cell lysate were detected. The data from three independent experiments were presented as the means ± SEM.; Kruskal–Wallis test followed by the Iman-Conover method for multiple comparison between groups was performed. ns, not significantly different.

P7C3 inhibited LPS-induced transcriptional activation of pro-inflammatory factors in BV2 cells. (A) BV2 cells were pretreated with P7C3 (0.1, 1, or 10 μM) for 2 h and then exposed to LPS (100 ng/mL) for 6 h. After treatment, cell lysate was collected to measure the mRNA levels of iNOS, COX-2, IL-6 and TNFα using qRT-PCR assays. The values are presented as the means ± SEM from three independent experiments. Kruskal–Wallis test followed by the Iman-Conover method for multiple comparison between groups was performed, *P < 0.05, **P < 0.01 vs. the group treated with LPS. (B) BV2 cells were pretreated with P7C3 (10 μM) for 2 h and then exposed to LPS (100 ng/mL) for 6 h. After culture, cell lysate was collected and the mRNA levels of Arg1, IL-10, CD206 were measured using qRT-PCR assays. (C) BV2 cells were administrated with P7C3 (10 μM) for 2 h followed by IL-4 (20 ng/mL) treatment or IL-4 (20 ng/mL) plus LPS (100 ng/mL) treatment for 6 h. The mRNA levels of Arg1, IL-10, CD206 in cell lysate were detected. The data from three independent experiments were presented as the means ± SEM.; Kruskal–Wallis test followed by the Iman-Conover method for multiple comparison between groups was performed. ns, not significantly different.